SUIT-005: Difference between revisions
From Bioblast
No edit summary |
Beno Marija (talk | contribs) No edit summary |
||
Line 2: | Line 2: | ||
|abbr=RP2-short | |abbr=RP2-short | ||
|description=[[File:1OctM;2D;3P;4S;5U;6Rot-.png|300px]] | |description=[[File:1OctM;2D;3P;4S;5U;6Rot-.png|300px]] | ||
|info='''A:''' when [[Malate anaplerotic pathway control state |malate-anaplerotic activity]] is zero ย | |info='''A:''' when [[Malate-anaplerotic pathway control state |malate-anaplerotic activity]] is zero ย | ||
}} | }} | ||
::: '''[[SUIT protocol pattern]]:''' 1OctM;2D;3P;4S;5U;6Rot- | ::: '''[[SUIT protocol pattern]]:''' 1OctM;2D;3P;4S;5U;6Rot- | ||
Line 22: | Line 22: | ||
== Strengths and limitations == | == Strengths and limitations == | ||
:::+ Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added. | :::+ Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added. | ||
:::+ The protocol provides information on F-OXPHOS capacity in the absence of a significant [[OXPHOS-capacity| OXPHOS-capacity]] in the [[malate anaplerotic pathway control state]]. | :::+ The protocol provides information on F-OXPHOS capacity in the absence of a significant [[OXPHOS-capacity| OXPHOS-capacity]] in the [[malate-anaplerotic pathway control state]]. | ||
:::+ [[FNS |FNS]] comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum [[OXPHOS-capacity| OXPHOS-]] and [[ET-capacity |ET-capacity]]. | :::+ [[FNS |FNS]] comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum [[OXPHOS-capacity| OXPHOS-]] and [[ET-capacity |ET-capacity]]. | ||
:::+ PM & S reconstitutes TCA cycle activity ([[PMS]]) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate. | :::+ PM & S reconstitutes TCA cycle activity ([[PMS]]) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate. |
Revision as of 12:05, 3 June 2020
Description
Abbreviation: RP2-short
Reference: A: when malate-anaplerotic activity is zero
- SUIT protocol pattern: 1OctM;2D;3P;4S;5U;6Rot-
The SUIT-005 protocols provide information on the F-pathway, the combined FN pathway, and the convergence FNS pathways in the OXPHOS state. FNS comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET-capacity. SUIT-005 can be extended with the CIV assay module.
Communicated by Iglesias-Gonzalez J and Gnaiger E (last update 2019-06-05)
Specific SUIT protocols
SUIT-005 O2 pfi D11
- SUIT-005 O2 pfi D011 for permeabilized fibers
Steps and respiratory states
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1OctM | OctML(n) | F(N) | FAO | 1OctM
|
2D | OctMP | F(N) | FAO | 1OCtM;2D
|
2c | OctMcP | F(N) | FAO | 1OCtM;2D;2c
|
3P | OctPMP | FN | F&CI | 1OctM;2D;2c;3P
|
4S | OctPMSP | FNS | F&CI&II | 1OctM;2D;2c;3P;4S
|
5U | OctPMSE | FNS | F&CI&II | 1OctM;2D;2c;3P;4S;5U
|
6Rot | SE | S | CII | 1OctM;2D;3P;4S;5U;6Rot
|
7Ama | ROX | 1OctM;2D;3P;4S;5U;6Rot;7Ama
|
Step | Respiratory state | Pathway control | ET-Complex | Comment |
---|---|---|---|---|
## AsTm | AsTmE | CIV | CIV | |
## Azd | CHB |
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- Pathway control
- ยป Electron transfer pathway
- ยป Fatty acid oxidation pathway control state, F
- ยป NADH electron transfer-pathway state, N
- ยป Succinate pathway control state, S
- ยป NS-pathway control state, NS
- ยป Glycerophosphate pathway control state, Gp
- ยป Complex IV single step, CIV
- ยป Anaplerotic pathway control state
- Pathway control
- Main fuel substrates
- ยป Glutamate, G
- ยป Glycerophosphate, Gp
- ยป Malate, M
- ยป Octanoylcarnitine, Oct
- ยป Pyruvate, P
- ยป Succinate, S
- Main fuel substrates
- Glossary
Strengths and limitations
- + Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added.
- + The protocol provides information on F-OXPHOS capacity in the absence of a significant OXPHOS-capacity in the malate-anaplerotic pathway control state.
- + FNS comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET-capacity.
- + PM & S reconstitutes TCA cycle activity (PMS) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate.
- + Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c.
- - F-OXPHOS capacity may be underestimated with Oct. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) & malate increased OXPHOS-capacity by 26% (Lemieux et al 2011).
- - SRotE may be underestimated if S is not saturating.
Compare SUIT protocols
References
MitoPedia concepts: MiP concept, SUIT protocol, Recommended
MitoPedia methods:
Respirometry